Thera-SAbDab

OFATUMUMAB

>   Structural Summary
TherapeuticOfatumumab
TargetMS4A1
Heavy ChainEVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK
100% seqID Fv Structure3giz [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2005
INN Year Recommended2006
Companies InvolvedGenmab, GlaxoSmithKline, Mundipharma International, National Cancer Centre (Singapore), Novartis, Roswell Park Cancer Institute, University Health Network
Conditions ApprovedChronic lymphocytic leukaemia
Conditions ActiveB-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Multiple sclerosis, Marginal zone B-cell lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma
Conditions DiscontinuedNeuromyelitis optica, Pemphigus vulgaris, Rheumatoid arthritis, Waldenstrom's macroglobulinaemia
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]